Safety Outcomes and Duration of Response in Combination Therapy vs. Monotherapy for BCG UR CIS +/- Papillary Disease
Key opinion leaders examine the comparative safety profiles and response durations of combination therapy versus monotherapy in the treatment of BCG-unresponsive carcinoma in situ with or without papillary disease.
EP: 1.Prevalence and Staging of Newly Diagnosed Bladder Cancer
EP: 2.Impact of BCG Therapy Shortage on the Management of High-Risk NMIBC
EP: 3.Recurrence and BCG Resistance in High-Risk NMIBC
EP: 4.Therapies Beyond BCG: FDA-Approved and Emerging Options
EP: 5.Cretostimogene, Grenadenorepvec, and Pembrolizumab for BCG-Unresponsive NMIBC: Overview of ASCO 2024 Data
EP: 6.CORE-001 Trial Participation and Eligibility Criteria
EP: 7.Comparing Cretostimogene and BCG Administration Methods
EP: 8.Results of the CORE-001 Trial: 24-Month Complete Response Rate and Duration of Response
EP: 9.Safety Outcomes and Duration of Response in Combination Therapy vs. Monotherapy for BCG UR CIS +/- Papillary Disease
EP: 10.Evaluating the Benefits of Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC Management
EP: 11.Evaluating Cretostimogene: BOND-003 and PIVOT-006 Trial Results
EP: 12.Managing BCG-Unresponsive NMIBC: Cretostimogene Monotherapy vs. Combination Therapy
Video content above is prompted by the following questions:
- Did safety outcomes with combination therapy vary from those observed with monotherapy cretostimogene or pembrolizumab?
- Can you please talk about the duration of response and how this compares to other agents that have been tested in BCG UR CIS +/- papillary disease?
Advancing bladder cancer care: The importance of integrating mental health support
September 9th 2024"I think the fact that we're having these conversations, that they are being talked about at national meetings, and that we are bringing the patient voice into this is hugely important," says Mary W. Dunn, MSN, NP-C, OCN, RN.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
